The efficacy and safety of somatostatin analog after axillary node dissection in breast cancer : a systematic review and meta-analysis

• 資料種別: 記事
• タイトル: The efficacy and safety of somatostatin analog after axillary node dissection in breast cancer : a systematic review and meta-analysis
• 著者・編者: Satsuki Hirono; Jun Watanabe; Atsushi Miki; Mikio Shiozawa; Naohiro Sata
• 出版事項: 日本 : Japan Medical Association
• 出版年月日等: 2023-07-14
• 出版年（W3CDTF）: 2023-07-14
• タイトル（掲載誌）: JMA Journal
• 巻号年月日等（掲載誌）: 6(3)
• 掲載巻: 6(3)
• ISSN（掲載誌）: 2433-3298
• ISSN-L（掲載誌）: 2433-328X
• 本文の言語コード: eng
• DOI: 10.31662/jmaj.2022-0219; https://doi.org/10.31662/jmaj.2022-0219
• 国立国会図書館永続的識別子: info:ndljp/pid/14495018; https://dl.ndl.go.jp/pid/14495018
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• 収集根拠: インターネット資料収集保存事業（WARP）
• 受理日（W3CDTF）: 2025-10-21T09:04:40+09:00
• 保存日（W3CDTF）: 2024-09-26
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: インターネット公開
• 遠隔複写可否（NDL）: 不可
• 掲載誌（URI）: https://warp.da.ndl.go.jp/info:ndljp/pid/13747952/www.jmaj.jp/detail.php?id=10.31662%2Fjmaj.2022-0219
• 掲載誌（国立国会図書館永続的識別子）: info:ndljp/pid/14495014; https://dl.ndl.go.jp/pid/14495014
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• 要約等: <p><b>Background</b>: Somatostatin analogs are expected to reduce lymphatic leakage. However, whether they can be used after axillary lymphadenectomy is unclear. This study aimed to assess the efficacy and safety of somatostatin analogs in axillary lymphadenectomy for breast cancer patients.</p><p><b>Methods</b>: We performed a random-effects meta-analysis by searching electronic databases for randomized trials and trial registries until June 2022. The primary outcomes were the volume of drained fluid, the duration of drainage, and seroma incidence. Bias was assessed using the Cochrane Collaboration's tool and the Grading of Recommendations, Assessment, Development, and Evaluations approach.</p><p><b>Results</b>: Six trials (738 participants) and one protocol without results were included. Somatostatin analogs may reduce the volume of drained fluid (mean difference = −22.07 mL, 95% confidence interval [CI] = −42.09 to −2.05; I² = 56%) while resulting in a slight-to-no difference in the duration of drainage (mean difference = −0.48 days, 95% CI = −1.43 to 0.46; I² = 87%) and seroma incidence (risk ratio = 0.91, 95% CI = 0.61-1.34; I² = 55%). The certainty of the evidence was low.</p><p><b>Conclusions</b>: There was limited evidence supporting somatostatin analogs for lymphorrhea after axillary lymphadenectomy. Multicenter randomized controlled trials are needed to confirm the efficacy and safety of somatostatin analogs after axillary lymphadenectomy.</p>
• DOI: 10.31662/jmaj.2022-0219
• オンライン閲覧公開範囲: インターネット公開
• 連携機関・データベース: 科学技術振興機構 : J-STAGE; http://www.jstage.jst.go.jp

• 要約等: <p><b>Background</b>: Somatostatin analogs are expected to reduce lymphatic leakage. However, whether they can be used after axillary lymphadenectomy is unclear. This study aimed to assess the efficacy and safety of somatostatin analogs in axillary lymphadenectomy for breast cancer patients.</p><p><b>Methods</b>: We performed a random-effects meta-analysis by searching electronic databases for randomized trials and trial registries until June 2022. The primary outcomes were the volume of drained fluid, the duration of drainage, and seroma incidence. Bias was assessed using the Cochrane Collaboration's tool and the Grading of Recommendations, Assessment, Development, and Evaluations approach.</p><p><b>Results</b>: Six trials (738 participants) and one protocol without results were included. Somatostatin analogs may reduce the volume of drained fluid (mean difference = −22.07 mL, 95% confidence interval [CI] = −42.09 to −2.05; I² = 56%) while resulting in a slight-to-no difference in the duration of drainage (mean difference = −0.48 days, 95% CI = −1.43 to 0.46; I² = 87%) and seroma incidence (risk ratio = 0.91, 95% CI = 0.61-1.34; I² = 55%). The certainty of the evidence was low.</p><p><b>Conclusions</b>: There was limited evidence supporting somatostatin analogs for lymphorrhea after axillary lymphadenectomy. Multicenter randomized controlled trials are needed to confirm the efficacy and safety of somatostatin analogs after axillary lymphadenectomy.</p>
• DOI: 10.31662/jmaj.2022-0219; https://doi.org/10.31662/jmaj.2022-0219
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（URI）: http://id.ndl.go.jp/digimeta/14495018; https://dl.ndl.go.jp/pid/14495018; https://www.jmaj.jp/download.php?id=10.31662/jmaj.2022-0219; https://search.jamas.or.jp/link/ui/2024269067
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org
• 書誌ID（NDLBibID）: 14495018; http://id.ndl.go.jp/bib/14495018